MADRIGAL PHARMACEUTICALS, INC.
Close on Oct 19, 2026
- Market cap
- $13.03B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 30, 2026 | Before market open | $364.30M | $1.99 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | Before market open | $311.30M | $-3.25 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 19, 2026 | Before market open | $321.10M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | Before market open | $287.30M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | $212.80M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 1, 2025 | Before market open | $137.30M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 26, 2025 | Before market open | $103.30M | $-2.71 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 31, 2024 | Before market open | $62.20M | $-4.92 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | Before market open | $14.60M | $-7.10 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | Before market open | – | $-7.38 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 28, 2024 | Before market open | – | – | – |
Press releases
Announcements Madrigal Pharmaceuticals filed with the SEC
Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Reports First -Quarter 2026 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Reports Third -Quarter 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Enters into Exclusive
Regulation FD disclosure · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH
Material agreement · Agreement terminated · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024
Results of operations · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Announces FDA Approval of
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Rezdiffr (resmetirom) FDA Approval Conference Call March 2024 NASDAQ: MDGL © 2024 Madrigal
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full
Results of operations · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023
Results of operations · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug
Other events · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of
Other events · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking
Other events · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year
Results of operations · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program
Material agreement · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Provides an Overview of Upcoming Resmetirom Data
Results of operations · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second
Results of operations · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial
Results of operations · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial
Results of operations · EX-99.1 to Form 8-K
Madrigal Pharmaceuticals Provides Corporate Update and Reports 2021 Third Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K